Owen Lockerbie

Riboflavin and UV-Light Based Pathogen Reduction: Extent and Consequence of DNA Damage at the Molecular Level

Vijay Kumar, Owen Lockerbie, Shawn D. Keil et al. · Photochemistry and Photobiology · 2004 · 227 citations

Life Sciences, Microbiology, Molecular Biology +16

Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen‐reduction technology‐treated apheresis platelet products

J. Li, D. de Korte, M. D. Woolum et al. · Vox Sanguinis · 2004 · 84 citations

Medicine, Hematology, Hematology Physiology +15

Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology

Junzhi Li, Owen Lockerbie, Dirk de Korte et al. · Transfusion · 2005 · 48 citations · Full text

Life Sciences, Biochemistry, Cell Biology +17

Investigation of Two Dosing Schedules of Vandetanib (ZD6474), an Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, in Combination with Irinotecan in a Human Colon Cancer Xenograft Model

Teresa Troiani, Natalie J. Serkova, Daniel L. Gustafson et al. · Clinical Cancer Research · 2007 · 42 citations

Medicine, Oncology, Pharmacology +17

Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases

Teresa Troiani, Owen Lockerbie, Mark Morrow et al. · Molecular Cancer Therapeutics · 2006 · 41 citations

Medicine, Oncology, Pharmacology +17